Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LALIT ANEJA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1386989820
CMS profile
1717328
Location
NORTH VENICE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,337.26

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,237.27 143
Education $99.99 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $320.69 12
PFIZER INC. $217.43 10
Daiichi Sankyo Inc. $188.34 7
Bayer Healthcare Pharmaceuticals Inc. $171.65 10
Syndax Pharmaceuticals, Inc. $145.62 1
SOBI, INC $133.18 6
Novartis Pharmaceuticals Corporation $118.15 6
BeOne Medicines USA, Inc. $117.53 8
AstraZeneca Pharmaceuticals LP $109.69 4
Merck Sharp & Dohme LLC $101.07 4
SEAGEN INC. $99.99 1
Incyte Corporation $96.43 4
E.R. Squibb & Sons, L.L.C. $91.97 5
Janssen Biotech, Inc. $90.31 5
Takeda Pharmaceuticals U.S.A., Inc. $83.92 3
ABBVIE INC. $79.11 4
Gilead Sciences, Inc. $76.81 3
PharmaEssentia USA Corporation $62.39 3
Astellas Pharma US Inc $60.60 3
PUMA BIOTECHNOLOGY, INC. $56.76 3
Exelixis Inc. $51.42 3
GENZYME CORPORATION $49.43 3
Kite Pharma, Inc. $47.86 2
ARRAY BIOPHARMA INC $42.89 2
Janssen Scientific Affairs, LLC $41.18 1
Geron Corporation $41.05 2
Lilly USA, LLC $39.00 2
Celgene Corporation $37.36 2
Pharmacosmos Therapeutics Inc. $37.30 2
Regeneron Healthcare Solutions, Inc. $35.35 1
Karyopharm Therapeutics Inc. $35.04 2
Genentech USA, Inc. $33.84 2
TerSera Therapeutics LLC $31.66 1
Immunocore Limited $27.37 1
Agios Pharmaceuticals, Inc. $27.20 1
JAZZ PHARMACEUTICALS INC. $26.72 1
BeiGene USA, Inc. $26.67 1
Dendreon Pharmaceuticals LLC $26.24 1
Myriad Genetic Laboratories, Inc. $25.84 1
Alexion Pharmaceuticals, Inc. $25.83 1
Stemline Therapeutics Inc. $25.24 1
Ipsen Biopharmaceuticals, Inc $24.74 1
Eisai Inc. $22.75 1
SpringWorks Therapeutics, Inc. $21.89 1
Aveo Pharmaceuticals, Inc. $20.78 1
EMD Serono, Inc. $19.70 1
Iovance Biotherapeutics, Inc. $19.17 1
Sumitomo Pharma America, Inc. $18.46 1
ARGENX US, INC. $18.17 1
Alnylam Pharmaceuticals Inc. $15.47 1

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LALIT ANEJA

NPI 1386989820 · CMS profile ID 1717328

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NORTH VENICE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386989820?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386989820?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386989820?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–144 of 144 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1386989820?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $3,337.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–144 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $13.7704/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200106042 CMS
Exelixis Inc. $16.8304/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218797599 CMS
GENZYME CORPORATION $14.5304/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233586594 CMS
GlaxoSmithKline, LLC. $26.6704/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190404216 CMS
Karyopharm Therapeutics Inc. $20.1304/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246647929 CMS
Gilead Sciences, Inc. $28.9004/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234445289 CMS
Eisai Inc. $22.7503/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244492536 CMS
AstraZeneca Pharmaceuticals LP $32.4903/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206778953 CMS
GlaxoSmithKline, LLC. $124.9903/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190499907 CMS
Incyte Corporation $20.2203/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226101847 CMS
Merck Sharp & Dohme LLC $23.7203/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238320558 CMS
Takeda Pharmaceuticals U.S.A., Inc. $32.8103/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223930034 CMS
Lilly USA, LLC $18.6703/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186691607 CMS
Daiichi Sankyo Inc. $28.5103/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197040171 CMS
ARRAY BIOPHARMA INC $14.8803/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229931980 CMS
Genentech USA, Inc. $18.2103/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211532837 CMS
GlaxoSmithKline, LLC. $25.2803/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190672399 CMS
Exelixis Inc. $17.5503/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218797597 CMS
Karyopharm Therapeutics Inc. $14.9103/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246647935 CMS
SOBI, INC $19.1603/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240248972 CMS
Gilead Sciences, Inc. $23.9103/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234485262 CMS
BeiGene USA, Inc. $26.6703/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202878800 CMS
Lilly USA, LLC $20.3302/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186741933 CMS
Regeneron Healthcare Solutions, Inc. $35.3502/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212863050 CMS
Bayer Healthcare Pharmaceuticals Inc. $25.9302/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225447493 CMS
Geron Corporation $17.5802/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238886657 CMS
Daiichi Sankyo Inc. $27.5402/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197043383 CMS
GlaxoSmithKline, LLC. $2.1002/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191795718 CMS
GlaxoSmithKline, LLC. $5.1402/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191799667 CMS
PUMA BIOTECHNOLOGY, INC. $19.3202/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251744154 CMS
Novartis Pharmaceuticals Corporation $23.9502/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200106040 CMS
GlaxoSmithKline, LLC. $31.9601/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191689182 CMS
Janssen Biotech, Inc. $14.3901/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175305792 CMS
Astellas Pharma US Inc $24.7601/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238726470 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.1101/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225447485 CMS
PFIZER INC. $11.1101/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229935311 CMS
AstraZeneca Pharmaceuticals LP $25.3601/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206570719 CMS
Dendreon Pharmaceuticals LLC $26.2401/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244997435 CMS
PFIZER INC. $19.6601/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229920798 CMS
SOBI, INC $23.1001/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240248966 CMS
Aveo Pharmaceuticals, Inc. $20.7801/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1199901778 CMS
Celgene Corporation $18.7801/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184568727 CMS
SEAGEN INC. $99.9901/10/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1229931990 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.0701/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225447481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,652.85 110
PY2020 $654.22 44
PY2021 $3,123.15 35
PY2022 $2,426.83 128
PY2023 $2,965.62 139
PY2024 $3,377.85 156
PY2025 $3,337.26 144

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $166,698.43 23
PY2024 Principal investigator $62,293.78 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) No dispute reported 06/30/2026 1185538765
Principal investigator 1 Janssen Research & Development, LLC $11,719.00 12/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329744
Principal investigator 1 Janssen Research & Development, LLC $3,818.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329695
Principal investigator 1 Genentech, Inc. $5,000.00 12/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
KRAS combo ph1b No dispute reported 06/30/2026 1211649968
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327225
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327522
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328641
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 11/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329288
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $361.69 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223288119
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328715
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327952
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 09/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329733
Principal investigator 1 Janssen Research & Development, LLC $2,912.67 08/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175327071
Principal investigator 1 Genentech, Inc. $4,063.00 08/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211649070
Principal investigator 1 Janssen Research & Development, LLC $7,330.00 07/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175329200
Principal investigator 1 Genentech, Inc. $596.00 07/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211649065
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $596.00 06/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223280760
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,285.00 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185538767
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 05/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185538761
Principal investigator 1 AstraZeneca Pharmaceuticals LP $11,967.07 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185538757
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,750.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185538769
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,600.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185538759
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,900.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185538763